Fallone C A, Loo V, Joseph L, Barkun J, Kostyk R, Barkun A N
Division of Gastroenterology, McGill University Health Centre, Montreal, Que.
Clin Invest Med. 1999 Oct;22(5):185-94.
In light of evidence that Helicobacter pylori treatment fails 5% to 20% of the time, the objective of this study was to determine predictors of unsuccessful H. pylori eradication and of duodenal ulcer recurrence.
Randomized, double-blind, placebo-controlled trial.
Gastroenterology services of 2 general hospitals in Montreal, Que.
All patients (aged 16 to 90) with an endoscopically proven duodenal ulcer within the previous year and H. pylori infection detected on antral biopsy were asked to participate; 85 were included.
Patients were randomized in double-blind fashion to 1 of 2 eradication therapies, consisting of metronidazole, bismuth subcitrate and either amoxicillin or placebo. Endoscopy was performed at follow-up every 3 months for 12 months.
Demographic data, characteristics of patients and disease, previous history and family history of ulcer disease, compliance at day 10 and day 28 of therapy; in vitro metronidazole resistance of H. pylori; eradication of H. pylori (determined by endoscopic biopsy 3 months after therapy); and ulcer recurrence within 12 months after therapy.
Metronidazole resistance (odds ratio [OR] 0.11, 95% confidence interval [CI] 0.017 to 0.69) was the only independent predictor of eradication. Compliance (as defined in the study), density of organisms on culture, as well as several other factors examined, were not significant predictors. Treatment group, although a significant factor on univariate analysis, was not an independent predictor on multivariate analysis, as there were relatively good eradication rates (82% and 97% among compliant patients) in both groups. With regard to ulcer recurrence, 3 independent predictors were identified: failed H. pylori eradication (OR 86.5, 95% CI 4.2 to 1769), unemployment (OR 13.2, 95% CI 1.8 to 95) and a family history of ulcer disease (OR 12.2, 95% CI 1.2 to 128).
The best predictor of ulcer recurrence is failure of H. pylori eradication, which, in turn, depends on metronidazole resistance. Hence, treatments containing metronidazole should be avoided in populations with high rates of metronidazole resistance. A family history of ulcer disease and unemployment were also predictors of ulcer recurrence, which suggests a potential role for treatment of contacts.
鉴于有证据表明幽门螺杆菌治疗失败率为5%至20%,本研究的目的是确定幽门螺杆菌根除失败及十二指肠溃疡复发的预测因素。
随机、双盲、安慰剂对照试验。
魁北克省蒙特利尔市2家综合医院的胃肠病科。
所有在前一年经内镜证实患有十二指肠溃疡且胃窦活检检测到幽门螺杆菌感染的患者(年龄16至90岁)均被邀请参与;共纳入85例。
患者以双盲方式随机分为2种根除治疗方案之一,治疗方案由甲硝唑、枸橼酸铋和阿莫西林或安慰剂组成。在12个月内每3个月进行一次随访内镜检查。
人口统计学数据、患者及疾病特征、溃疡病既往史和家族史、治疗第10天和第28天的依从性;幽门螺杆菌对甲硝唑的体外耐药性;幽门螺杆菌的根除情况(治疗后3个月通过内镜活检确定);治疗后12个月内溃疡复发情况。
甲硝唑耐药性(比值比[OR]0.11,95%置信区间[CI]0.017至0.69)是根除的唯一独立预测因素。依从性(如研究中所定义)、培养物中细菌密度以及所检查的其他几个因素均不是显著的预测因素。治疗组虽然在单因素分析中是一个显著因素,但在多因素分析中不是独立预测因素,因为两组中依从性好的患者根除率相对较高(分别为82%和97%)。关于溃疡复发,确定了3个独立预测因素:幽门螺杆菌根除失败(OR 86.5,95%CI 4.2至1769)、失业(OR 13.2,95%CI 1.8至95)和溃疡病家族史(OR 12.2,95%CI 1.2至128)。
溃疡复发的最佳预测因素是幽门螺杆菌根除失败,而这又取决于甲硝唑耐药性。因此,在甲硝唑耐药率高的人群中应避免使用含甲硝唑的治疗方案。溃疡病家族史和失业也是溃疡复发的预测因素,这表明对有接触者进行治疗可能具有潜在作用。